Progyny, Inc. (NASDAQ:PGNY) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Progyny, Inc. (NASDAQ:PGNY) have received an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $29.80.

Several analysts recently commented on the company. KeyCorp boosted their price target on Progyny from $30.00 to $32.00 and gave the company an “overweight” rating in a research note on Thursday, January 8th. BTIG Research restated a “buy” rating on shares of Progyny in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Citizens Jmp raised Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 target price on the stock in a report on Tuesday, January 20th. Finally, Zacks Research downgraded Progyny from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th.

Progyny Stock Down 2.6%

NASDAQ PGNY opened at $20.98 on Friday. The stock has a market cap of $1.81 billion, a P/E ratio of 33.30, a PEG ratio of 1.36 and a beta of 0.96. Progyny has a twelve month low of $17.98 and a twelve month high of $28.75. The company’s 50-day simple moving average is $25.01 and its 200 day simple moving average is $23.28.

Insider Transactions at Progyny

In other Progyny news, CFO Mark S. Livingston sold 21,303 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $25.50, for a total value of $543,226.50. Following the completion of the transaction, the chief financial officer directly owned 48,358 shares of the company’s stock, valued at approximately $1,233,129. The trade was a 30.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 22,046 shares of company stock worth $561,691. 9.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of PGNY. Dimensional Fund Advisors LP raised its stake in shares of Progyny by 12.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,712,039 shares of the company’s stock worth $43,966,000 after buying an additional 184,679 shares during the last quarter. Integrated Quantitative Investments LLC grew its holdings in Progyny by 27.4% during the 4th quarter. Integrated Quantitative Investments LLC now owns 45,937 shares of the company’s stock worth $1,180,000 after acquiring an additional 9,890 shares during the period. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Progyny during the 4th quarter valued at $1,965,000. New York State Common Retirement Fund lifted its stake in shares of Progyny by 19.6% in the 4th quarter. New York State Common Retirement Fund now owns 24,970 shares of the company’s stock valued at $641,000 after purchasing an additional 4,100 shares during the period. Finally, Campbell & CO Investment Adviser LLC boosted its position in shares of Progyny by 19.3% in the 4th quarter. Campbell & CO Investment Adviser LLC now owns 27,010 shares of the company’s stock worth $694,000 after purchasing an additional 4,362 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.